Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GFER | P55789 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486563 | 0.87 | NOTUM (0.46) | MAPTSMN1; SMN2ALDH1A1GFERHTT | |
| SCHEMBL16003487 | 0.86 | GFER (0.62) | MAPTSMN1; SMN2ALDH1A1GFERHTT | |
| SCHEMBL631834 | 0.85 | MAPT (0.68) | MAPTSMN1; SMN2ALDH1A1GFERHTT | |
| SCHEMBL3986081 | 0.85 | IP6K1 (0.53) | MAPTSMN1; SMN2ALDH1A1GFERHTT | |
| SCHEMBL15358734 | 0.85 | MAPT (0.63) | MAPTSMN1; SMN2ALDH1A1GFERHTT | |
| SCHEMBL23123759 | 0.83 | IP6K1 (0.50) | MAPTSMN1; SMN2ALDH1A1GFERHTT | |
| SCHEMBL11297155 | 0.81 | IP6K1 (0.49) | MAPTSMN1; SMN2ALDH1A1GFERHTT | |
| SCHEMBL11299225 | 0.81 | GAA (0.59) | MAPTSMN1; SMN2ALDH1A1GFERHTT | |
| SCHEMBL11299382 | 0.81 | IP6K1 (0.49) | MAPTSMN1; SMN2ALDH1A1GFERHTT | |
| SCHEMBL5237104 | 0.81 | ADAMTS5 (0.52) | MAPTSMN1; SMN2ALDH1A1GFERHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | disclosed |
| US-20150175545-A1 | Preparation Method of Fluoro-Substituted Deuterated Diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO LTD (CN) | 2015-06-25 | — | — | US | disclosed |
| WO-2015038417-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | disclosed |
| EP-2665727-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012097684-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | SRC, PTK2, FYN | MAPT 3391/4885SMN1; SMN2 1653/4885ALDH1A1 3377/4885 |
| US-20150175545-A1 | Preparation Method of Fluoro-Substituted Deuterated Diphenylurea | CCND3, UBE2D3, VDR | MAPT 4194/4885SMN1; SMN2 3123/4885ALDH1A1 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.